Draig Therapeutics Raises $140M Series A to Advance Neuropsychiatric Drug Pipeline

Draig Therapeutics, a UK-based biotech company, secured $140 million in Series A funding to develop new treatments for neuropsychiatric conditions3.

The round was led by Access Biotechnology, with participation from Sanofi Ventures, Canaan Partners, Schroders Capital, and SR One3.

The company’s lead candidate, DT-101, is a positive allosteric modulator of the AMPA receptor, which has already completed a Phase 1 study for major depressive disorder13.

Draig plans to use this funding to advance DT-101 into Phase II (mid-stage) clinical trials within 20253.

Two additional GABA_A modulators are in preclinical development, with clinical trials planned for 2026; their specific indications have not yet been disclosed3.

Draig is a spinout from Cardiff University’s Medicines Discovery Institute and SV Health Investors, who were also early backers3.

Sources:

1. https://www.statnews.com/2025/06/18/biotech-news-makary-draig-psychedelics-depression-bio-vaccines-the-readout/

3. https://www.biospace.com/business/draig-takes-flight-with-140m-series-a-to-advance-neuropsych-drugs